OLFML3 and neoplasm: Interestingly, we observed that one of the eight mice treated with anti-PD-1 antibody did not develop a primary tumor, while, remarkably, three of the eight mice did not develop a primary tumor with the combination of anti-PD-1 and anti-OLFML3.